PDCD1 and neoplasm: They show that, in contrast to existing therapeutic antibodies to PD-1, the MW11-h317 antibody interaction with PD-1 is dependent on PD-1 glycoyslation on Asn58 and further demonstrate its efficiency against tumours in mouse xenografts.